Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-03-21 00:00:00 ET · period of report 2022-03-17 · accession 0000899243-22-011705 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-03-21 | 2022-03-17 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $250.11 | -2,833 | 47.4K | -6% | -$708.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | S | D | 34 | $251.24 | 47,356 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-17 | S | D | 2,799 | $250.10 | 47,390 | D | — | — | (F3) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F2) Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55). |